Dominari Holdings, a brokerage tied to the Trump family, faces mounting pressure from the House China Committee after CEO Anthony Hayes declined to cooperate with a probe into alleged stock manipulation schemes involving Chinese IPOs. The committee demanded records on due diligence policies, trading data, and nominee account red flags by March 11, but Hayes emphasized underwriting Chinese listings contributes minimally to Dominari’s revenue, implying reluctance to engage further. Three days past the deadline, the firm has yet to submit documentation, leaving lawmakers to weigh escalating the investigation via subpoena or risking political backlash from Trump allies.

The Trump family connection—not disclosed initially—has complicated the committee’s calculus. While the probe centers on firms that listed Chinese companies later accused of market manipulation, Dominari’s high-profile ties to DJT’s inner circle raise stakes. Sources suggest committee members may have only learned of the link after *Financial Times* reporting, prompting hesitation to provoke the Trump orbit. Revere and D Boral, other underwriters named, have not commented, but Dominari’s silence intensifies scrutiny.

The standoff highlights tensions between congressional oversight and political realities. Subpoenaing Dominari could provoke accusations of targeting Trump associates, yet inaction risks undermining the panel’s credibility. The firm’s defense—that underwriting Chinese stocks is a minor revenue stream—underscores a broader debate: should investigations prioritize transparency or avoid entanglements with powerful figures?

This situation reflects a fragile balance between market integrity and partisan optics. As the Chinese IPO market remains volatile, the committee’s handling of Dominari may set precedents for regulating foreign-listed firms. For now, the lack of cooperation—and the Trump family’s shadow—looms large over Capitol Hill’s regulatory efforts.